Business

GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board

Newly Appointed Members Include Leaders in Vaccine Immunology, T-Cell Science, and Clinical Research ATLANTA, GA - December 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen va...

articleGeovax Labs, Inc.December 10, 20253/company/geovax-labs-inc/news/geovax-announces-addition-renowned-global-140000731
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board

About this update from Geovax Labs, Inc.

[{"type":"image","caption":"","headline":"GeoVax Highlights 2026 as a Pivotal Year for Progress","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Newly Appointed Members Include Leaders in Vaccine Immunology, T-Cell Science, and Clinical Research","length":100,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - December 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancers, today announced an update to its Scientific Advisory Board (SAB), welcoming internationally recognized experts whose work spans vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised-host medicine.","length":432,"tagName":"p"},{"type":"text","content":"This strategic expansion is designed to support GeoVax's current and future development efforts with MVA and its multi-antigen MVA vector platform for vaccines targeting biothreat pathogens and vulnerable or currently underserved populations such as those from low- and middle-income countries, and immunocompromised patients. Future additions to the GeoVax SAB will support its oncology immunotherapy pipeline.","length":415,"tagName":"p"},{"type":"text","content":"Newly Announced SAB Members","length":27,"tagName":"p"},{"type":"text","content":"Joining Prof. Teresa Lambe, PhD, OBE, FMedSci - Calleva Head of Vaccine Immunology, Oxford Vaccine Group / Jenner Institute, University of Oxford, whose appointment to the GeoVax SAB was previously announced, are the following:","length":227,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Alessandro Sette, Dr of Biological Sciences - Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":135,"olType":false},{"type":"text","content":"An authority in T-cell epitope mapping and immune correlates of protection, Dr. Sette leads the NIH Immune Epitope Database (IEDB) and is w...

More updates from Geovax Labs, Inc.

GeoVaximmunocompromised patientsinfectious diseasesJenner Instituteunderserved populationsOxford Vaccine GroupScientific Advisory Boardhuman immunologyimmunotherapiesUniversity of OxfordUniversity of Liverpoolbiotechnology company